Lupin gets USFDA nod for treatment of Kidney patient

Sevelamer hydrochloride tablets are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

64
USFDA
Picture: Pixabay

Last Updated on June 18, 2021 by The Health Master

Global pharma major Lupin Limited announced that it has received approval for its sevelamer hydrochloride tablets, 400 mg and 800 mg from the United States Food and Drug Administration (USFDA) to market a generic equivalent of Renagel tablets, 400 mg and 800 mg, of Genzyme Corporation.

The product will be manufactured at Lupin’s facility in Nagpur, India.

Sevelamer hydrochloride tablets are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

Sevelamer hydrochloride tablets had estimated annual sales of US$ 80 million in the US (IQVIA MAT March 2021).

Aleor gets USFDA nod for Testosterone Topical Solution

Avenue Therapeutics gets complete response letter from USFDA for IV Tramadol

Natco gets USFDA nod for Carfilzomib Injection

Lupin gets warning letter from USFDA for Somerset facility

Lupin gets USFDA nod for generic drug to treat HIV infection

Glenmark gets USFDA nod for Theophylline ER tablets

Schedules: All types of Clinical Trials

Schedules: All types of Drugs

Schedules: All types of Cosmetics

Schedules: All types of Medical Devices

Govt to amend Schedule K to exempt Antiseptics from sale license

India should immediately start Drug Brand Name Registry: Experts

Subscribe for daily free updates

Telegram
WhatsApp
Facebook
LinkedIn

Enter your email address:

Delivered by FeedBurner